title: Cutaneous lupus erythematosus.
abstract: Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.
authors: Department of Dermatology, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA. Christopher.hansen@hsc.utah.edu
authors: Christopher B
authors: CB
authors: Hansen
authors: Kevin W
authors: KW
authors: Dahle
mesh_terms: D000962:Antimalarials / Q000627:therapeutic use*; D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000209:etiology / Q000473:pathology / Q000628:therapy; D008178:Lupus Erythematosus, Cutaneous / Q000473:pathology / Q000628:therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D013472:Sunlight / Q000009:adverse effects
chemical_list: D000962:Antimalarials; D003879:Dermatologic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents